{"name":"MU-JHU CARE","slug":"mu-jhu-care","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Long-acting Cabotegravir injection","genericName":"Long-acting Cabotegravir injection","slug":"long-acting-cabotegravir-injection","indication":"HIV-1 infection in treatment-naive and treatment-experienced adults (long-acting injectable formulation for maintenance therapy)","status":"marketed"},{"name":"TDF/3TC/EFV or DTG or NVP","genericName":"TDF/3TC/EFV or DTG or NVP","slug":"tdf-3tc-efv-or-dtg-or-nvp","indication":"HIV-1 infection treatment and suppression","status":"marketed"}]}],"pipeline":[{"name":"Long-acting Cabotegravir injection","genericName":"Long-acting Cabotegravir injection","slug":"long-acting-cabotegravir-injection","phase":"marketed","mechanism":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA.","indications":["HIV-1 infection in treatment-naive and treatment-experienced adults (long-acting injectable formulation for maintenance therapy)"],"catalyst":""},{"name":"TDF/3TC/EFV or DTG or NVP","genericName":"TDF/3TC/EFV or DTG or NVP","slug":"tdf-3tc-efv-or-dtg-or-nvp","phase":"marketed","mechanism":"This is a combination antiretroviral regimen containing nucleoside reverse transcriptase inhibitors (TDF/3TC), a non-nucleoside reverse transcriptase inhibitor (EFV or NVP), or an integrase strand transfer inhibitor (DTG) that blocks HIV replication by inhibiting key viral enzymes.","indications":["HIV-1 infection treatment and suppression"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}